Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00068029 · ClinicalTrials.gov registry record · Phase 4
Pegvisomant And Sandostatin LAR Combination Study
A Phase 4 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 4
- Development phase
- 75
- Enrollment target
NCT00068029 is a Phase 4 study that has completed, run by Pfizer. The registered enrollment target is 75 participants.
The verdict
NCT00068029, a Phase 4 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 75 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the safety and tolerability of combination therapy with Sandostatin LAR plus Pegvisomant to that of Sandostatin LAR alone or Pegvisomant alone.
Interventions
- DRUG Pegvisomant
- DRUG Sandostatin LAR
- DRUG Pegvisomant/ Sandostatin LAR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2003-10 |
| Est. Completion | 2006-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00068029
The ClinicalTrials.gov registry entry for NCT00068029 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Pegvisomant is the first listed.
NCT00068029 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00068029 about?
NCT00068029 is a clinical study titled "Pegvisomant And Sandostatin LAR Combination Study". The purpose of this study is to compare the safety and tolerability of combination therapy with Sandostatin LAR plus Pegvisomant to that of Sandostatin LAR alone or Pegvisomant alone.
What is the current status of trial NCT00068029?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 75 participants. The study started on 2003-10. Estimated completion is 2006-05.
What interventions are being tested in trial NCT00068029?
The interventions under investigation include: Pegvisomant (DRUG), Sandostatin LAR (DRUG), Pegvisomant/ Sandostatin LAR (DRUG).
Who is sponsoring clinical trial NCT00068029?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.